Laboratory and clinical data for anti-AQP1 seropositive patients.

F, female; LETM, longitudinally extensive transverse myelitis; M, male; MS, multiple sclerosis; NMO, neuromyelitis optica; NT, not tested.
aAll 22 patients tested negative for serum anti-AQP-4 autoantibodies in the two-step RIPA and confirmed by both a commercial and an in-house CBA.
bThe anti-AQP1 positivity of the sera was also confirmed by the more sensitive two-step RIPA for anti-AQP1 antibodies (not shown).
cAccording to the Methods and Figure 8.
dCalculated by multiplying anti-AQP1 titers (in 6th column) by the percentages of the extracellularly binding antibodies (in 7th column).
eBinding of sera to synthetic peptides corresponding to AQP1 segments (from Figure 9B). Underlined loops are extracellular.